




Figure 1

Tigatuzumab MB design

A

MB design
DNA ratio 4:1:1




Figure 2a




Figure 2b




Figure 2b (continued)




Figure 2c

Conatumumab MB bipartite (MB) design




Figure 3a




Figure 3b




Figure 3b (continued)




Figure 3c




Figure 4A




Figure 4B




Figure 5